UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2017

TRACON Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36818	34-2037594
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
8910 University Center Lane, Suite 700		
San Diego, California		92122
(Address of principal executive offices)		(Zip Code)
	telephone number, including area code: (858) 5	
heck the appropriate box below if the Form 8-K filing is intended	to simultaneously satisfy the filing obligation of	the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Se	curities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under the Exchange	ange Act (17 CFR 240.14a-12)	

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

Charles P. Theuer, M.D., Ph.D., President and Chief Executive Officer of TRACON Pharmaceuticals, Inc. ("TRACON"), and other executive officers will be presenting information that includes an estimate of TRACON's December 31, 2016 cash, cash equivalents and short-term investments and outstanding debt principal balances, at various upcoming meetings beginning January 9, 2017. The information is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

Charles P. Theuer, M.D., Ph.D., and other executive officers will be presenting the information attached as Exhibit 99.1 to this Current Report on Form 8-K at various upcoming meetings beginning January 9, 2017.

By furnishing this information, TRACON makes no admission as to the materiality of any information in this report. The information contained in this report and the exhibit hereto is intended to be considered in the context of TRACON's filings with the Securities and Exchange Commission and other public announcements that TRACON makes, by press release or otherwise, from time to time. TRACON undertakes no duty or obligation to publicly update or revise the information contained in this report or the exhibit hereto, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosure.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description of Exhibit

99.1 Corporate Presentation, dated January 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRACON Pharmaceuticals, Inc.

Dated: January 9, 2017

By: <u>/s/ Charles P. Theuer, M.D., Ph.D.</u> Charles P. Theuer, M.D., Ph.D. President and Chief Executive Officer

Exhibit	
No.	Description
99.1	Corporate Presentation, dated January 2017

Exhibit 99.1

TRACON PHARMACEUTICALS January 2017



NASDAQ: TCON

Forward-Looking Statements


This presentation contains statements that are, or may be deemed to be, "forward-looking statements." In some cases these forwardlooking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential," or, in each case, their negatives or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition, business strategy, current and prospective product candidates, planned clinical trials and preclinical activities, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success of development activities and business strategies, plans and objectives of management for future operations, and future results of anticipated product development efforts, including potential benefits derived therefrom. These statements involve substantial known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risks associated with conducting clinical trials, whether any of our product candidates will be shown to be safe and effective, our ability to finance continued operations, our reliance on third parties for various aspects of our business, competition in our target markets, our ability to protect our intellectual property, and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including under the heading "Risk Factors". In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

Investment Highlights

TRC105 Phase 3	angiosarcom	loglin biology – Open Phase 3 trial under SPA in orphan drug indication o a; multiple ongoing Phase 2 trials in combination with VEGF inhibitors, a rently generating > \$17B annually	f
	Oncology	Clinical data from more than 400 patients treated show tolerability and promising anti-tumor activity with each of four VEGF inhibitors	
	Ophthalmology	Partnered with Santen, Phase 1/2 wet AMD trial enrolling	
	Fibrosis	Reverses fibrosis and improves survival in preclinical models	
TRC102 Phase 2		le inhibitor of DNA repair being studied in Phase 2 in glioblastoma and a with NCI support	
TRC253 IND Filed		le inhibitor of mutated and wild-type Androgen Receptor e 1/2 start in early 2017	
Product Developmen Platform		ve clinical operations, regulatory and QA capabilities lopment expertise basis for deal with Janssen	
TRACON			3

Broad Pipeline with Multiple Expected Near-term Readouts





 1 Partnered with Santen Pharmaceutical Co., Ltd. (Santen) 2 Janssen Pharmaceutica N.V. (Janssen) has a buyback option

4

Complementing VEGF Inhibition Represents a Substantial **Potential Commercial Opportunity for TRC105**

Indication	Approved VEGF Inhibitors	2015 VEGF Inhibitor Revenue ¹ (Growth vs 2014)
2 nd Line Renal Cell Carcinoma	Inlyta	\$430 million (5%)
1 st Line Hepatocellular Carcinoma	Nexavar	\$1.0 billion ² (0%)
2 nd Line Soft Tissue Sarcoma	Votrient	~\$150 million ³
Colorectal Cancer, Lung Cancer	Avastin, Cyramza, Zaltrap, Stivarga	>\$5 billion ⁴
Wet AMD	Eylea Lucentis	\$4.1 billion (47%) \$3.6 billion (-15%)

Substantial opportunity to build upon multiple established VEGF inhibitor franchises by improving patient outcomes through improved inhibition of angiogenesis


 Company reports, SEC filings, DataMonitor.
 Nexavar is approved in HCC, RCC and thyroid cancer. The majority of Nexavar's sales are in HCC.
 Votrient is approved in both HCC and advanced STS. Estimated sales for Votrient in STS (based on 2014 total sales less DataMonitor estimates in RCC)





4 Based on company estimates of sales by indication for Avastin and Cyramza.

Endoglin: Essential Non-VEGF Angiogenic Target


- Endoglin is expressed on endothelial cells and is essential for angiogenesis
 - Selectively expressed on proliferating vessels in cancer and AMD; up-regulated following VEGF inhibition
 - Unfavorable prognostic marker
- Attenuated endoglin expression causes Osler-Weber-Rendu syndrome which is associated with improved cancer survival (31% reduced risk of death)
- Persistent expression on tumor vessels results in progression despite VEGF inhibition, while knockdown of endoglin sensitizes tumors to VEGF inhibition
- Targeting VEGF and endoglin concurrently has been shown to improve angiogenesis inhibition







Angiosarcoma



Normal Human Liver

Human Liver Cancer


Human AMD Membrane


TRC105: Our Lead Endoglin Antibody

 TRC105 binds a precise endoglin epitope to inhibit BMP binding and VEGF- and fibroblast growth factor (FGF)-induced angiogenesis




 TRC105 also potently mediates antibody-dependent cell mediated cytotoxicity (ADCC)





Decreased phosphorylated SMAD 1/5/8 allows unopposed phospho-SMAD 2/3 signaling to restore a quiescent phenotype

TRC105 Tiered Clinical Development Strategy



Combinations Well Tolerated and Evidence of Clinical Activity with Multiple VEGF inhibitors

Combination	Well Tolerated	Signs of Activity in Phase 1b/2	Ongoing Development
TRC105 + Votrient	\checkmark	Durable complete responses in angiosarcoma	Randomized global Phase 3 trial in angiosarcoma under SPA open for enrollment
TRC105 + Avastin	\checkmark	Tumor reductions in Avastin-refractory patients; durable complete response in GTN patient	Randomized Phase 2 trial in GBM; global Phase 2 trial in GTN
TRC105 + Inlyta	\checkmark	PFS of 11.3 mos. and ORR of 29% in clear cell RCC exceeded reported Inlyta ¹ PFS of 4.8 mos. and ORR of 11%	Randomized Phase 2 trial in clear cell RCC
TRC105 + Nexavar	\checkmark	ORR of 40% at top dose levels of TRC105 in HCC exceeded reported Nexavar ² ORR of 2%	Phase 2 trial of TRC105 + Nexavar in HCC

¹ Inlyta results from separate Inlyta Phase 3 AXIS trial following VEGFR treatment. Inlyta results from head-to-head comparison in same clinical trial may differ.



² Nexavar results from separate Phase 3 SHARP trial. Nexavar results from head-to-head comparison in same clinical trial may differ.9

VEGF Inhibitors Have Limited Activity in Angiosarcoma


VEGF Inhibitor	Study	Patient Population	Activity
Votrient ¹	Retrospective analysis (CTOS 2016)	Angiosarcoma (n = 40)	 ORR = 20% (No CRs) PFS = 3.0 months OS = 9.9 months
Votrient	Retrospective analysis (ASCO 2014)	Soft tissue sarcoma, including 6 angiosarcoma patients	• No CR's
Nexavar	Single agent study (Maki 2009)	Angiosarcoma (n = 37)	• ORR = 14% (1/37 CR) • PFS = 3.8 months
Nexavar	Single agent study (French sarcoma group)	Angiosarcoma (n = 41)	Cutaneous angiosarcoma • ORR = 15% (2/26 CR) • PFS = 1.8 months <u>Visceral angiosarcoma</u> • ORR = 13% (No CRs) • PFS = 3.8 months
Avastin	Single agent study (Agulnik 2013)	Angiosarcoma (n = 23)	• ORR = 9% (No CRs) • PFS = 3.0 months



¹ Votrient is the only VEGF inhibitor approved for the treatment of soft tissue sarcoma based on the superior PFS versus placebo (4.6 versus 1.6 months) in the Phase 3 PALETTE study.

TRC105 + Votrient Angiosarcoma Phase 1b/2

- Combination well-tolerated; data presented at ASCO 2016 and CTOS 2016
- · Angiosarcoma, an endothelial sarcoma, has been very responsive



Duration on study is calculated from date of consent to date of withdrawal
 Last response assessment used as date of progression for ongoing pts with CR to calculate mPFS

Data as of CTOS (November 2016)


TRC105 + Votrient Phase 1b/2 Observations



Data as of CTOS (November 2016)




Patient #6 ongoing at month 10 with significant tumor reduction




Day 0

Day 84




TRC105 + Avastin in Gestational Trophoblastic Neoplasia

- A 37 year old woman with widely metastatic choriocarcinoma who progressed following five chemotherapeutic regimens and stem cell transplant developed a complete response to treatment with TRC105 + Avastin, following four months of treatment, that remains ongoing for more than 18 months; second patient did not respond to treatment
- Global Phase 2 study in gestational trophoblastic neoplasia, including choriocarcinoma, is enrolling with response rate as the primary endpoint




TRC105 + Inlyta in Renal Cell Carcinoma

- · 18 patients treated in a Phase 1b clinical trial who failed at least one VEGF inhibitor
- Partial response rate by RECIST of 29% (4 of which were in the fourth line setting)
 - Exceeded partial response rate of Inlyta following VEGFR TKI treatment in the Inlyta Phase 3 AXIS trial of 11%
- Improved activity in clear cell (including 4 RECIST PRs) and exploratory analysis indicated two biomarkers (baseline TGF-β R3 and osteopontin) correlated with activity
- · Median PFS in clear cell RCC of 11.3 months
 - Exceeded PFS of Inlyta following VEGFR TKI treatment in the Inlyta Phase 3 AXIS trial of 4.8 months




Ongoing Phase 2 Multicenter Randomized Trials



TRC105 + Nexavar in Hepatocellular Carcinoma

- 20 patients treated (of whom 14 were evaluable by RECIST) in a Phase 1/2 clinical trial .
- Partial response rate by RECIST of 40% (treated with 10 or 15 mg/kg TRC105) - Exceeded partial response rate of Nexavar in Phase 3 pivotal studies of 2 - 3%
- Initiated multicenter trial in hepatocellular carcinoma of up to 33 patients to confirm response rate and to potentially justify a randomized Phase 3 trial



Maximum Percentage Change in Target Lesion Size in Hepatocellular

Development in AMD Partnered with Santen

- Data from Ophthotech indicate that vision in wet AMD can be improved by targeting complementary pathways in combination with VEGF inhibitors
- TRC105 preclinical proof of concept established in a model of AMD
- Santen, a global ophthalmology company with \$1.6 billion in annual revenue, will lead global development and commercialization efforts for DE-122 (ophthalmic formulation of TRC105) in wet AMD and other eye diseases
- Deal terms
 - \$13 million received thus far
 - Santen pays for all development costs
 - Up to \$152 million in additional milestone payments
 - Royalties in the high single digits to low teens
- Phase 1/2 PAVE trial is enrolling; expect completion in 2H 2017
- Expect Santen to initiate Phase 2 AVANTE study in 2H 2017

TRC102: Reversing Resistance to Chemotherapy

- Small molecule designed to reverse resistance to chemotherapy and complement poly ADPribose polymerase (PARP) inhibitors
- Inhibits base excision repair, a dominant pathway of DNA repair that allows for resistance to alkylating chemotherapy (e.g., Temodar) and antimetabolite chemotherapy (e.g., Alimta)

Combination	Well Tolerated	Signs of Activity in Phase 1b/2	Ongoing Development
TRC102 + Alimta (Published in <i>Investigational New</i> <i>Drugs</i> , 2012)	\checkmark	Stable disease in some patients with squamous cell lung cancer, a tumor type where Alimta is inactive	Phase 2 trial with Alimta in mesothelioma
TRC102 + Fludara (Presented at ASH 2014)	\checkmark	Partial response and stable disease in some patients previously treated with Fludara	
TRC102 + Temodar (Presented at ASCO 2016)	\checkmark	Partial response in some patients with lung, KRAS+ colorectal and ovarian cancer	Phase 2 trial with Temodar in glioblastoma

Deal with Janssen

- TRC253 and TRC694 in-licensed from Janssen
 - TRC253 is a Phase 1-ready antagonist of the F876L and other AR mutations that are resistance mechanisms for Xtandi[®] and ARN-509 (apalutamide)
 - TRC694 is a selective inhibitor of NF-kB-inducing kinase (NIK)
- TRACON was chosen because of our efficient product development platform
- \$5M equity investment made by JJDC

TRC253 Janssen has rights to re-acquire TRC253 following Phase 1 for \$45M Additional potential milestones of \$137.5M and low single digit royalty If kept by TRACON, we would owe regulatory and commercial milestones of up to \$45M and a low

TRACON


single digit royalty to Janssen

TRC253: Novel Androgen Receptor (AR) Mutant Inhibitor


 Designed to treat AR resistant prostate cancer

- Occurs in ~10% of mCRPC cases

- Active against wild-type AR and many clinically relevant ligand binding domain mutants
- Clear path to POC in targeted population using a companion diagnostic



Multiple Mechanisms of Action





Multiple Expected Near-Term Clinical Readouts

	Companion Therapy	Indication	2017	2018
2	Votrient	Angiosarcoma	Phase 3	*
timat	Inlyta	RCC	Phase 2B	
rotux	Avastin	GBM	Phase 28	
05 (ca	Nexavar	HCC	Phase 1B/2	*
TRC105 (carotuximab)	Avastin	Gestational Neoplasia	Phase 2	
	Avastin + Carbo/Taxol	Lung	Phase 1B	•
	Afinitor + Femara	Breast	Phase 18/2	•
102	Alimta	Mesothelioma	Phase 2	➡
TRC102	Temodar	GBM	Phase 2	➡
TRC 253		Prostate	Phase 1/2	*
TRACON	Ņ ,	Phase 2 or 3 data	expected	

TRC694: Novel NF-kB Inducing Kinase (NIK) Inhibitor


- NIK pathway is dysregulated in hematologic malignancies
 - Multiple myeloma (~12-20% of cases), mantle cell lymphoma (~17%), diffuse large B-cell lymphoma (~9-15%), CLL (~4% at diagnosis, higher later)
- <1 nM affinity,<10 nM cellular potency
- Clear path to POC in targeted population using a companion diagnostic





TRC205 Development in Fibrosis


- Endoglin expression on activated fibroblasts is the basis for development of endoglin antibodies in fibro-proliferative disorders
 - Idiopathic pulmonary fibrosis, liver fibrosis (including NASH), renal fibrosis, end-stage pulmonary hypertension, hypertrophic cardiomyopathy, scleroderma, non-systolic heart failure
- Targeting endoglin with TRC105 reverses cardiac fibrosis caused by pulmonary artery constriction (PAC) and prolongs survival in mice



- Reduction in cutaneous neurofibromatosis seen in sarcoma patient treated with TRC105 + Votrient
- TRC205 is an IgG4 version of TRC105 that is active in preclinical models of NASH significantly reduced the NAFLD Activity Score and demonstrated hepatoprotective, antiinflammatory and anti-NASH effects

TRACON Kapur NK, et al. J Am Heart Assoc. 2014.

Capital Efficient Product Development Platform



Significant Cost Savings to TRACON

Expected Milestones Across All Programs

Milestone	Expected Timi	ing
SPA from FDA for TRC105 Phase 3 pivotal trial in angiosarcoma	1H 2017	\checkmark
Initiate dosing in TRC105 Phase 3 pivotal trial in angiosarcoma	1H 2017	
Initiate dosing in TRC253 Phase 1/2 trial in prostate cancer	1H 2017	
Top-line data from TRC105 randomized Phase 2 trial in GBM	1H 2017	
Data presentation from TRC105 Phase 1 trial in lung cancer	1H 2017	
Complete DE-122 Phase 1/2 PAVE study in wet AMD (Santen)	2H 2017	
Initiate dosing in DE-122 Phase 2 AVANTE study in wet AMD (Santen)	2H 2017	
Top-line data from TRC105 randomized Phase 2 trial in RCC	2H 2017	
Complete dose escalation in TRC253 Phase 1/2 trial in prostate cancer	2H 2017	

Financial Overview (as of December 31, 2016)

Ticker	TCON (NASDAQ)
Cash, Cash Equivalents and Short-term Investments	\$44.4 million*
Debt – Outstanding Principal	\$8.0 million*
Common Shares O/S	16.1 million*
Covering Analysts	Brian Abrahams (Jefferies) Jim Birchenough (Wells Fargo) Bert Hazlett (BTIG) Chad Messer (Needham) Tom Shrader (Stifel)

*These amounts are preliminary, have not been audited and are subject to change upon completion of the audit of our consolidated financial statements as of and for the year ended December 31, 2016.

Experienced Leadership Team



Investment Highlights

TRC105 Phase 3	angiosarcom	doglin biology – Open Phase 3 trial under SPA in orphan drug indication o a; multiple ongoing Phase 2 trials in combination with VEGF inhibitors, a rently generating > \$17B annually	f
	Oncology	Clinical data from more than 400 patients treated show tolerability and promising anti-tumor activity with each of four VEGF inhibitors	
	Ophthalmology	Partnered with Santen, Phase 1/2 wet AMD trial enrolling	
	Fibrosis	Reverses fibrosis and improves survival in preclinical models	
TRC102 Phase 2		ile inhibitor of DNA repair being studied in Phase 2 in glioblastoma and a with NCI support	
TRC253 IND Filed		le inhibitor of mutated and wild-type Androgen Receptor e 1/2 start in early 2017	
Product Developmen Platform		ive clinical operations, regulatory and QA capabilities lopment expertise basis for deal with Janssen	
TRACON			29

TRACON PHARMACEUTICALS January 2017



NASDAQ: TCON



TRACON


31

TRACON is a Leader in Endoglin Biology

Drug Candidate	Sponsor	Mechanism of Action	Clinical Status
TRACON's end	loglin antibody pipel	ine	
TRC105		Targets endoglin (receptor for TGF-β and bone morphogenic protein [BMP]) to inhibit cell signaling and <u>mediate ADCC</u>	Combination with VEGF Inhibitors Votrient (Phase 3 - Angiosarcoma) Inlyta (Phase 2b - RCC) Avastin (Phase 2b - GBM) Nexavar (Phase 2 - HCC) Avastin (Phase 2 - GTN)
TRC205		Like TRC105, but IgG4	Lead pre-clinical antibody for fibrosis
Other product	candidates targeting	the endoglin pathway in	n development
PF03446962	Pfizer	Targets ALK1 (endoglin co-receptor)	Combination with VEGF Inhibitors Stivarga (Phase 1b - Colorectal)
Dalantercept		Targets the endoglin ligand BMP	Combination with VEGF Inhibitors Inlyta (Phase 2b - RCC)

Gestational Trophoblastic Neoplasia (GTN): Phase 2

- Previously treated (at least one chemotherapy regimen) GTN .
- Primary Endpoint: ORR to single agent TRC105 or the combination of TRC105 + Avastin .
- Key Secondary Endpoint: PFS



TRC105 Tiered Product Development Strategy

	Companion Therapy	Indications	Commercial Rationale	Target Efficacy Threshold for Approval/Reimbursement ⁴
Ultra-Orphan	Votrient	Angiosarcoma	Endoglin expressed on angiosarcoma; Votrient approved as single agent; short time to endpoint (PFS ¹)	67% improvement in PFS
	Avastin	Gestational Neoplasia	Endoglin expressed on choriocarcinoma; short time to expected endpoint (ORR ²)	15% response rate
Fast-to-Market	Inlyta	Renal cell: 2 nd Line	Inlyta approved as single agent; short time to endpoint (PFS) in a vascular tumor	40% improvement in PFS
	Avastin	GBM: 2 nd Line	Avastin approved as single agent; short time to endpoint (OS ³) in a vascular tumor	30% improvement in OS
	Nexavar	Hepatocellular: 1 st Line	Nexavar approved as single agent in first line; short time to endpoint (OS)	30% improvement in OS
Large Market	Afinitor + Femara	Breast cancer: Neoadjuvant	Neoadjuvant setting allows approval based on pathologic complete response rate (pCR)	30% improvement in pCR
	Avastin + chemo	Lung cancer: 1 st Line	Significant Avastin commercial franchise	30% improvement in OS



¹Progression free survival. ²Overall response rate. ³Overall survival. ⁴TRACON internal targets based on marketed drugs for similar indications. Subject to regulatory and healthcare payor requirements.

TRC102: Reversing Resistance to Chemotherapy

